Black Rock Inc. Relmada Therapeutics, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 573,314 shares of RLMD stock, worth $361,187. This represents 0.0% of its overall portfolio holdings.
Number of Shares
573,314
Previous 578,188
0.84%
Holding current value
$361,187
Previous $2.69 Million
36.05%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding RLMD
# of Institutions
49Shares Held
6.3MCall Options Held
0Put Options Held
0-
Acadian Asset Management LLC Boston, MA1.23MShares$773,5940.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.21MShares$761,0870.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$311,9410.03% of portfolio
-
Geode Capital Management, LLC Boston, MA302KShares$190,1860.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny288KShares$181,4400.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $18M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...